Patient-derived Orthotopic Xenograft Models for Cancer of Unknown Primary Precisely Distinguish Chemotherapy, and Tumor-targeting A1-R is Superior to First-line Chemotherapy

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2018 May 2

PMID 29713497

Citations 4

Authors

Kentaro Miyake

Tasuku Kiyuna

Masuyo Miyake

Kei Kawaguchi

Sang Nam Yoon

Zhiying Zhang

Kentaro Igarashi

Sahar Razmjooei

Sintawat Wangsiricharoen

Takashi Murakami

Yunfeng Li

Scott D Nelson

Tara A Russell

Arun S Singh

Yukihiko Hiroshima

Masashi Momiyama

Ryusei Matsuyama

Takashi Chishima

Shree Ram Singh

Itaru Endo

Fritz C Eilber

Robert M Hoffman

Affiliations

Soon will be listed here.

Abstract

Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective for this CUP patient. We also demonstrated that A1-R was more effective against the CUP tumor than first-line chemotherapy. Our results indicate that A1-R has clinical potential for CUP, a resistant disease that requires effective therapy.

Citing Articles

Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice.

Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N In Vivo. 2025; 39(2):640-647.

PMID: 40010967 PMC: 11884439. DOI: 10.21873/invivo.13869.

The Combination of Tumor-targeting A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells and .

Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N In Vivo. 2024; 39(1):102-109.

PMID: 39740880 PMC: 11705149. DOI: 10.21873/invivo.13807.

Accurate and Safe Tumor Targeting of Orally-administered A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude Mice.

Morinaga S, Zhao M, Mizuta K, Kang B, Sato M, Bouvet M In Vivo. 2024; 38(6):2601-2609.

PMID: 39477429 PMC: 11535920. DOI: 10.21873/invivo.13736.

Efficacy of Tumor-Targeting A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models.

Murakami T, Hiroshima Y, Miyake K, Kiyuna T, Endo I, Zhao M Cells. 2019; 8(6).

PMID: 31208120 PMC: 6628209. DOI: 10.3390/cells8060599.

Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer.

Yoshii Y, Matsumoto H, Yoshimoto M, Oe Y, Zhang M, Nagatsu K J Nucl Med. 2019; 60(10):1437-1443.

PMID: 30850497 PMC: 6785796. DOI: 10.2967/jnumed.118.225045.

References

Greco F, Burris 3rd H, Litchy S, Barton J, Bradof J, Richards P . Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002; 20(6):1651-6. DOI: 10.1200/JCO.2002.20.6.1651. View

Pavlidis N, Briasoulis E, Hainsworth J, Greco F . Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39(14):1990-2005. DOI: 10.1016/s0959-8049(03)00547-1. View

Fu X, Guadagni F, Hoffman R . A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992; 89(12):5645-9. PMC: 49349. DOI: 10.1073/pnas.89.12.5645. View

Hainsworth J, Spigel D, Farley C, Thompson D, Shipley D, Greco F . Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007; 25(13):1747-52. DOI: 10.1200/JCO.2006.09.3047. View

Lequin D, Fizazi K, Toujani S, Souquere S, Mathieu M, Hainaut P . Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary). BMC Cancer. 2007; 7:225. PMC: 2241840. DOI: 10.1186/1471-2407-7-225. View

Varadhachary G, Raber M, Matamoros A, Abbruzzese J . Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008; 9(6):596-9. DOI: 10.1016/S1470-2045(08)70151-7. View

Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K . Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle. 2009; 8(6):870-5. DOI: 10.4161/cc.8.6.7891. View

Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou A, Ioannidis J, Pavlidis N . Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009; 35(7):570-3. DOI: 10.1016/j.ctrv.2009.05.005. View

Fernandez A, Assenov Y, Martin-Subero J, Balint B, Siebert R, Taniguchi H . A DNA methylation fingerprint of 1628 human samples. Genome Res. 2011; 22(2):407-19. PMC: 3266047. DOI: 10.1101/gr.119867.110. View

10.

Kurahashi I, Fujita Y, Arao T, Kurata T, Koh Y, Sakai K . A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. PLoS One. 2013; 8(5):e63249. PMC: 3650062. DOI: 10.1371/journal.pone.0063249. View

11.

Hiroshima Y, Zhao M, Maawy A, Zhang Y, Katz M, Fleming J . Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J Cell Biochem. 2014; 115(7):1254-61. DOI: 10.1002/jcb.24769. View

12.

Ettinger D, Handorf C, Agulnik M, Bowles D, Cates J, Cristea M . Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014; 12(7):969-74. DOI: 10.6004/jnccn.2014.0093. View

13.

Varadhachary G, Raber M . Carcinoma of unknown primary site. N Engl J Med. 2014; 371(21):2040. DOI: 10.1056/NEJMc1411384. View

14.

Hoffman R . Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015; 15(8):451-2. DOI: 10.1038/nrc3972. View

15.

Ma Y, Zhou W, He S, Xu W, Xiao J . Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival. Int J Cancer. 2016; 139(6):1423-30. DOI: 10.1002/ijc.30176. View

16.

Groschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C . Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with amplification. Cold Spring Harb Mol Case Stud. 2016; 2(6):a001180. PMC: 5111004. DOI: 10.1101/mcs.a001180. View

17.

Zheng J, Nguyen V, Jiang S, Park S, Tan W, Hong S . Two-step enhanced cancer immunotherapy with engineered secreting heterologous flagellin. Sci Transl Med. 2017; 9(376). DOI: 10.1126/scitranslmed.aak9537. View

18.

Subbiah I, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong D . Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017; 4(5-6):47-56. PMC: 5538848. DOI: 10.18632/oncoscience.352. View

19.

Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Miyake M . The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and deletion: Direction for third-line patient therapy. Oncotarget. 2017; 8(61):103129-103136. PMC: 5732717. DOI: 10.18632/oncotarget.20789. View